SRZN
Surrozen, Inc.
Price Chart
Latest Quote
$23.25
-0.79 (-3.29%)
Current Price
| Previous Close | $24.04 |
| Open | $24.69 |
| Day High | $24.69 |
| Day Low | $22.51 |
| Volume | 197,676 |
Stock Information
| Shares Outstanding | 11.61M |
| Total Debt | $6.78M |
| Cash Equivalents | $106.91M |
| Revenue | $7.49M |
| Net Income | $-342.56M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $269.94M |
| EPS (TTM) | $-36.59 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $164.00M |
| Sales | $7.49M |
| Income | $-342.56M |
| Book/sh | $-24.21 |
| Cash/sh | $9.21 |
| Employees | 44 |
Financial Ratios
| Quick Ratio | 11.70 |
| Current Ratio | 11.91 |
Returns & Margins
| ROA | -22.82% |
| Operating Margin | -209.12% |
Ownership
| Insider Ownership | 3.18% |
| Institutional Ownership | 101.88% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.83 |
| P/S | 36.02 |
| P/B | -0.96 |
Analyst Data
| Recommendation | none |
| Target Price | $42.50 |
Technical Indicators
| SMA20 | $24.03 |
| SMA50 | $27.87 |
| SMA200 | $21.32 |
| RSI | 39.27 |
| ATR | 2.1736 |
| Shares Float | 5.10M |
| Short Float | 8.64% |
| Short Ratio | 5.82 |
| Volatility | 0.51 |
| Rel Volume | 2.16 |
Performance History
| Week | -0.51% |
| Month | -9.07% |
| Quarter | -12.69% |
| 6 Months | +3.98% |
| YTD | +7.89% |
| Year | +152.17% |
| 3 Years | +148.00% |
| 5 Years | -84.34% |
| 10 Years | -84.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $23.25 | 246,500 |
| 2026-06-17 | $24.04 | 246,800 |
| 2026-06-16 | $22.75 | 104,800 |
| 2026-06-15 | $23.14 | 183,200 |
| 2026-06-12 | $23.39 | 71,100 |
| 2026-06-11 | $23.37 | 84,400 |
| 2026-06-10 | $21.77 | 53,400 |
| 2026-06-09 | $21.50 | 82,300 |
| 2026-06-08 | $20.69 | 145,800 |
| 2026-06-05 | $21.52 | 97,000 |
| 2026-06-04 | $24.38 | 77,300 |
| 2026-06-03 | $24.57 | 78,400 |
| 2026-06-02 | $23.15 | 122,600 |
| 2026-06-01 | $24.71 | 88,700 |
| 2026-05-29 | $26.21 | 360,300 |
| 2026-05-28 | $26.16 | 49,300 |
| 2026-05-27 | $26.46 | 38,300 |
| 2026-05-26 | $26.17 | 50,600 |
| 2026-05-22 | $26.37 | 53,100 |
| 2026-05-21 | $27.09 | 46,700 |
| 2026-05-20 | $27.05 | 92,800 |
| 2026-05-19 | $25.57 | 196,300 |
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-Ã, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
đ° Latest News
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate
Simply Wall St. âĸ 2026-05-17T14:17:57Z
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-04-15T11:06:00Z
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?
Zacks âĸ 2026-04-14T13:28:00Z
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
MarketBeat âĸ 2026-02-15T14:10:20Z
We're Hopeful That Surrozen (NASDAQ:SRZN) Will Use Its Cash Wisely
Simply Wall St. âĸ 2025-12-08T13:54:09Z
Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the company
Simply Wall St. âĸ 2025-08-30T12:00:29Z
We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth
Simply Wall St. âĸ 2025-07-01T12:51:49Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $3,477,000 | $10,655,000 | $0 | $12,500,000 |
| Operating Revenue | $3,477,000 | $10,655,000 | $0 | $12,500,000 |
| Expenses | ||||
| Total Expenses | $45,569,000 | $36,194,000 | $43,028,000 | $56,839,000 |
| Other Income Expense | $-202,954,000 | $-39,718,000 | $-2,354,000 | $7,554,000 |
| Other Non Operating Income Expenses | $-26,312,000 | $-39,718,000 | $398,000 | $7,554,000 |
| Net Non Operating Interest Income Expense | $3,020,000 | $1,693,000 | $2,340,000 | $781,000 |
| Operating Expense | $45,569,000 | $36,194,000 | $43,028,000 | $56,839,000 |
| General And Administrative Expense | $16,204,000 | $15,062,000 | $15,798,000 | $19,826,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Net Interest Income | $3,020,000 | $1,693,000 | $2,340,000 | $781,000 |
| Interest Income | $3,020,000 | $1,693,000 | $2,340,000 | $781,000 |
| Normalized Income | $-65,384,000 | $-63,564,000 | $-40,290,000 | $-36,004,000 |
| Net Income From Continuing And Discontinued Operation | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Total Operating Income As Reported | $-42,092,000 | $-25,539,000 | $-45,780,000 | $-44,339,000 |
| Net Income Common Stockholders | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Net Income | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Net Income Including Noncontrolling Interests | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Net Income Continuous Operations | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Pretax Income | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Interest Income Non Operating | $3,020,000 | $1,693,000 | $2,340,000 | $781,000 |
| Operating Income | $-42,092,000 | $-25,539,000 | $-43,028,000 | $-44,339,000 |
| Special Income Charges | - | $0 | $-2,752,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-32.37 | $-21.67 | $-21.33 | $-15.60 |
| Basic EPS | $-32.37 | $-21.67 | $-21.33 | $-15.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $135,087,000 | $-24,097,000 | $-38,365,000 | $-42,384,000 |
| Total Unusual Items | $-176,642,000 | $0 | $-2,752,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-176,642,000 | $0 | $-2,752,000 | $0 |
| Reconciled Depreciation | $537,000 | $1,442,000 | $1,911,000 | $1,955,000 |
| EBITDA (Bullshit earnings) | $-41,555,000 | $-24,097,000 | $-41,117,000 | $-42,384,000 |
| EBIT | $-42,092,000 | $-25,539,000 | $-43,028,000 | $-44,339,000 |
| Diluted Average Shares | $7,478,000 | $2,933,000 | $2,018,000 | $2,314,800 |
| Basic Average Shares | $7,478,000 | $2,933,000 | $2,018,000 | $2,314,800 |
| Diluted NI Availto Com Stockholders | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Gain On Sale Of Security | $-176,642,000 | - | - | - |
| Research And Development | $29,365,000 | $21,132,000 | $27,230,000 | $37,013,000 |
| Selling General And Administration | $16,204,000 | $15,062,000 | $15,798,000 | $19,826,000 |
| Other Gand A | $16,204,000 | $15,062,000 | $15,798,000 | $19,826,000 |
| Restructuring And Mergern Acquisition | - | $0 | $2,752,000 | $0 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Total Assets | $98,726,000 | $48,467,000 | $46,080,000 | $89,435,000 |
| Total Non Current Assets | $7,167,000 | $9,535,000 | $4,948,000 | $8,130,000 |
| Other Non Current Assets | $734,000 | $1,019,000 | $1,090,000 | $1,232,000 |
| Financial Assets | $0 | $153,000 | $0 | - |
| Current Assets | $91,559,000 | $38,932,000 | $41,132,000 | $81,305,000 |
| Prepaid Assets | $2,106,000 | $1,826,000 | $2,357,000 | $2,733,000 |
| Receivables | $208,000 | $2,541,000 | $2,152,000 | $1,978,000 |
| Accounts Receivable | $0 | $2,039,000 | $2,152,000 | $1,978,000 |
| Cash Cash Equivalents And Short Term Investments | $89,245,000 | $34,565,000 | $36,043,000 | $75,838,000 |
| Cash And Cash Equivalents | $89,245,000 | $34,565,000 | $36,043,000 | $24,690,000 |
| Other Current Assets | - | $671,000 | $580,000 | $756,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $6,639,000 | $8,469,000 | $3,379,000 | $5,602,000 |
| Long Term Debt And Capital Lease Obligation | $5,349,000 | $6,640,000 | $882,000 | $3,376,000 |
| Current Debt And Capital Lease Obligation | $1,290,000 | $1,829,000 | $2,497,000 | $2,226,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $286,488,000 | $69,847,000 | $8,145,000 | $13,434,000 |
| Total Non Current Liabilities Net Minority Interest | $276,558,000 | $62,532,000 | $997,000 | $3,702,000 |
| Other Non Current Liabilities | $158,662,000 | - | - | - |
| Derivative Product Liabilities | $112,547,000 | $55,892,000 | $115,000 | $326,000 |
| Current Liabilities | $9,930,000 | $7,315,000 | $7,148,000 | $9,732,000 |
| Other Current Liabilities | $289,000 | $191,000 | $292,000 | $581,000 |
| Payables And Accrued Expenses | $8,351,000 | $5,295,000 | $4,359,000 | $6,925,000 |
| Payables | $728,000 | $306,000 | $525,000 | $658,000 |
| Accounts Payable | $728,000 | $306,000 | $525,000 | $658,000 |
| Equity | ||||
| Common Stock Equity | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Total Equity Gross Minority Interest | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Stockholders Equity | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Retained Earnings | $-527,285,000 | $-285,259,000 | $-221,695,000 | $-178,653,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-241,000 |
| Other Equity Adjustments | - | - | - | $-241,000 |
| Other | ||||
| Ordinary Shares Number | $9,774,537 | $3,262,000 | $2,063,000 | $2,005,866 |
| Share Issued | $9,774,537 | $3,262,000 | $2,063,000 | $2,005,866 |
| Tangible Book Value | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Invested Capital | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Working Capital | $81,629,000 | $31,617,000 | $33,984,000 | $71,573,000 |
| Capital Lease Obligations | $6,639,000 | $8,469,000 | $3,379,000 | $5,602,000 |
| Total Capitalization | $-187,762,000 | $-21,380,000 | $37,935,000 | $76,001,000 |
| Additional Paid In Capital | $339,522,000 | $263,879,000 | $259,630,000 | $254,895,000 |
| Capital Stock | $1,000 | $0 | $0 | $0 |
| Common Stock | $1,000 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $5,349,000 | $6,640,000 | $882,000 | $3,376,000 |
| Current Capital Lease Obligation | $1,290,000 | $1,829,000 | $2,497,000 | $2,226,000 |
| Current Accrued Expenses | $7,623,000 | $4,989,000 | $3,834,000 | $6,267,000 |
| Net PPE | $6,433,000 | $8,363,000 | $3,858,000 | $6,898,000 |
| Accumulated Depreciation | $-8,375,000 | $-7,847,000 | $-7,368,000 | $-11,355,000 |
| Gross PPE | $14,808,000 | $16,210,000 | $11,226,000 | $18,253,000 |
| Leases | $1,116,000 | $1,116,000 | $1,116,000 | $7,052,000 |
| Other Properties | $13,176,000 | $14,578,000 | $9,592,000 | $10,783,000 |
| Machinery Furniture Equipment | $516,000 | $516,000 | $518,000 | $418,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $208,000 | $502,000 | $0 | - |
| Other Short Term Investments | - | - | $0 | $51,148,000 |
| Investments And Advances | - | - | - | $0 |
| Buildings And Improvements | - | - | - | $3,268,000 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-30,372,000 | $-17,654,000 | $-40,761,000 | $-44,873,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-30,244,000 | $-17,628,000 | $-40,363,000 | $-44,145,000 |
| Cash Flow From Continuing Operating Activities | $-30,244,000 | $-17,628,000 | $-40,363,000 | $-44,145,000 |
| Operating Gains Losses | $131,219,000 | $39,847,000 | $-385,000 | $-7,890,000 |
| Investing Activities | ||||
| Capital Expenditure | $-128,000 | $-26,000 | $-398,000 | $-728,000 |
| Investing Cash Flow | $-128,000 | $-26,000 | $51,723,000 | $38,309,000 |
| Cash Flow From Continuing Investing Activities | $-128,000 | $-26,000 | $51,723,000 | $38,309,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $83,780,000 | $16,043,000 | $0 | $0 |
| Financing Cash Flow | $85,052,000 | $16,176,000 | $276,000 | $-2,565,000 |
| Cash Flow From Continuing Financing Activities | $85,052,000 | $16,176,000 | $276,000 | $-2,565,000 |
| Net Common Stock Issuance | $83,780,000 | $16,043,000 | $-4,000 | $-2,607,000 |
| Common Stock Issuance | $83,780,000 | $16,043,000 | $0 | $0 |
| Repurchase Of Capital Stock | - | $0 | $-4,000 | $-2,607,000 |
| Net Other Financing Charges | - | - | - | $-101,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $89,933,000 | $35,253,000 | $36,731,000 | $25,095,000 |
| Beginning Cash Position | $35,253,000 | $36,731,000 | $25,095,000 | $33,496,000 |
| Changes In Cash | $54,680,000 | $-1,478,000 | $11,636,000 | $-8,401,000 |
| Proceeds From Stock Option Exercised | $1,272,000 | $133,000 | $280,000 | $42,000 |
| Net PPE Purchase And Sale | $-128,000 | $-26,000 | $-398,000 | $-728,000 |
| Purchase Of PPE | $-128,000 | $-26,000 | $-398,000 | $-728,000 |
| Change In Working Capital | $3,153,000 | $-836,000 | $-3,929,000 | $-8,418,000 |
| Change In Other Current Liabilities | $-1,830,000 | $-2,344,000 | $-2,223,000 | $-2,191,000 |
| Change In Other Current Assets | $72,000 | $71,000 | $62,000 | $-379,000 |
| Change In Payables And Accrued Expense | $2,645,000 | $828,000 | $-2,683,000 | $-3,820,000 |
| Change In Accrued Expense | $2,503,000 | $1,056,000 | $-2,550,000 | $-1,782,000 |
| Change In Payable | $142,000 | $-228,000 | $-133,000 | $-2,038,000 |
| Change In Account Payable | $142,000 | $-228,000 | $-133,000 | $-2,038,000 |
| Change In Prepaid Assets | $-67,000 | $1,111,000 | $915,000 | $-50,000 |
| Change In Receivables | $2,333,000 | $-502,000 | $0 | $-1,978,000 |
| Changes In Account Receivables | $2,333,000 | $-502,000 | $0 | $-1,978,000 |
| Other Non Cash Items | $72,116,000 | $1,369,000 | $1,273,000 | $1,587,000 |
| Stock Based Compensation | $3,835,000 | $4,114,000 | $4,372,000 | $4,517,000 |
| Asset Impairment Charge | $922,000 | $0 | $169,000 | $0 |
| Depreciation Amortization Depletion | $537,000 | $1,442,000 | $1,911,000 | $1,955,000 |
| Depreciation And Amortization | $537,000 | $1,442,000 | $1,911,000 | $1,955,000 |
| Gain Loss On Investment Securities | $131,219,000 | $39,734,000 | $-211,000 | $-7,890,000 |
| Net Foreign Currency Exchange Gain Loss | $0 | $113,000 | $-174,000 | - |
| Net Income From Continuing Operations | $-242,026,000 | $-63,564,000 | $-43,042,000 | $-36,004,000 |
| Common Stock Payments | - | $0 | $-4,000 | $-2,607,000 |
| Net Investment Purchase And Sale | - | $0 | $52,121,000 | $39,037,000 |
| Sale Of Investment | - | $0 | $80,165,000 | $68,637,000 |
| Purchase Of Investment | - | $0 | $-28,044,000 | $-29,600,000 |
| Amortization Of Securities | - | $0 | $-732,000 | $108,000 |
| Depreciation | - | - | $1,911,000 | $1,955,000 |
Fetched: 2026-06-18